Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus

doi:10.12998/wjcc.v10.i20.6900

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 20

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7077)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-4) series.

Item

Count

PDF

371

WORD

HTML

3711

Figures (1-8)

659

Tables (1-4)

563

Sum=5382

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

411

Download

1290

Sum=1701

Jul 16, 2022 (publication date) through Mar 2, 2026

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Systematic Reviews

World J Clin Cases. Jul 16, 2022; 10(20): 6900-6914
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6900

Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus

Xiao-Yan Cui, Xiao Wu, Dan Lu, Dan Wang

Xiao-Yan Cui, Hebei Institute for Drug and Medical Device Control, Shijiazhuang 050011, Hebei Province, China

Xiao Wu, Department of Basic Medical, HE’s University, Shenyang 110163, Liaoning Province, China

Dan Lu, College of Clinical, HE’s University, Shenyang 110163, Liaoning Province, China

Dan Wang, College of Human Kinesiology, Shenyang Sport University, Shenyang 110102, Liaoning Province, China

Author contributions: Wang D and Lu D performed the writing and revising of the manuscript; Wu X and Cui XY contributed to the design of the work and performed overall supervision; Wang D wrote and revised the paper.

Supported by the Central Government guides local S&T Program of Hebei Province, No. 216Z2501G; and Scientific Research Project of Hebei Provincial Market Supervision Administration, No. 2021YJ11.

Conflict-of-interest statement: The authors declare no conflict of interest, financial or otherwise.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Corresponding author: Dan Wang, PhD, Teacher, College of Human Kinesiology, Shenyang Sport University, No. 36 Jinqiansong East Road Sujiatun District, Shenyang 110102, Liaoning Province, China. 595680903@qq.com

Received: December 28, 2021
Peer-review started: December 28, 2021
First decision: January 23, 2022
Revised: February 2, 2022
Accepted: April 15, 2022
Article in press: April 15, 2022
Published online: July 16, 2022
Processing time: 188 Days and 18.3 Hours

ARTICLE HIGHLIGHTS

Research background

Sanqi and Huangjing (SQHJ) ameliorate diabetes mellitus (DM) in vivo and in vitro respectively. However, the combined effects of SQHJ on DM are unclear.

Research motivation

To provide an objective basis for the treatment of DM with traditional Chinese medicine.

Research objectives

To explore the potential mechanism of Panax notoginseng (Sanqi in Chinese) and Polygonati Rhizoma (Huangjing in Chinese) for the treatment of DM using network pharmacology.

Research methods

Active components of SQHJ and targets were predicted and screened by network pharmacology using the Traditional Chinese Medicine Systems Pharmacology Analysis Platform, DisGeNET database, STRING database, Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes enrichment analysis.

Research results

Of 18 active components from 157 SQHJ components, 187 potential targets for active components and 115 overlapping genes for active components and DM were screened. Quercetin, beta-sitosterol, baicalein and so on were the major active components. The mechanism of intervention of SQHJ in treating DM may involve nine core targets (TP53, AKT1, CASP3, TNF, interleukin-6, PTGS2, MMP9, JUN, and MAPK1). The treatment of DM using SQHJ primarily involved 16 GO enriched terms and 13 related pathways.

Research conclusions

SQHJ treats DM by targeting TP53, AKT1, CASP3, and TNF and participating pathways in leishmaniasis, pathways in cancer, and so on.

Research perspectives

SQHJ is effective for the treatment of DM. In the future, experiments will be needed to verify these results.